Reducing COPD Readmission Rates: Using a COPD Care Service During Care Transitions

Edward C. Portillo, PharmD; Andrew Wilcox, PharmD; Ellina Seckel, PharmD; Amanda Margolis, PharmD; Jean Montgomery, MD; Prakash Balasubramanian, MD; Geri Abshire, MSN, RN; Jim Lewis, RRT; Christopher Hildebrand, MD; Sameer Mathur, MD; Alan Bridges, MD; and Sujani Kakumanu, MD

A chronic obstructive pulmonary disease care service improves timely access to follow-up care and patient education at the time of transition from hospital to home.

COPD is the third leading cause of death worldwide and has an associated treatment cost of $9,800 per patient per year in the US. Within 5 years of hospital discharge for a COPD exacerbation, the rehospitalization risk is 44%, and the mortality rate is 55%. COPD affects more than 11 million Americans, and the disease prevalence among US veterans is 3-fold higher.

Patients hospitalized for COPD have a 30-day readmission rate of 22.6%. Given the high patient burden, COPD was added to the Medicare Hospital Readmission Reductions Program in 2015, resulting in financial penalties for COPD readmissions within 30 days of hospital discharge. Ensuring timely access to follow-up care has been shown to significantly reduce risk for hospital readmissions. However, in a national review of Medicare claims, only 50% of patients readmitted to the hospital had a primary care provider (PCP) follow-up visit within 30 days of their hospital discharge. Despite the need to provide prompt follow-up during the transition from hospital to home, gaps within the health care system create barriers to providing timely postdischarge care. These gaps include breakdowns in practitioner and patient communication, lengthy time to follow-up, and incomplete medication reconciliation.

To address this unmet need, clinics and hospitals require solutions that can be implemented quickly, using the resources of their current clinical models. Pharmacists and registered nurses (RNs) within the US federal health care system are well positioned for involvement in the postdischarge care of high-risk patients with COPD. Ambulatory care practitioners within the US Department of Veterans Affairs (VA) health care system are integrated into patient care teams (PACT). Each team consists of a PCP, pharmacist, RN, social worker, dietitian, licensed practical nurse, and medical scheduling support assistant. Each PACT team works together to provide patient education, chronic disease management, and medication optimization, and each team member contributes their unique training and expertise.

Interprofessional care is considered an integral method to improve health outcomes through effective teamwork and communication. Although interprofessional interventions are cited extensively in the literature as highlighting medicine and nursing, a gap exists in the exploration of pharmacist contributions within interprofessional teams. The incorporation of clinical pharmacists in the literature is especially limited when considering transitions of care and the patient medical home. Given the critical and collaborative role pharmacists play within the PACT medical home, the COPD CARE (Chronic Obstructive Pulmonary Disease Coordinated Access to Reduce Exacerbations) service provides an opportunity to leverage pharmacists with a scope of practice who coordinate transitions of care for patients with COPD. The service was designed to be collaborative within the PACT model and timely triage of patients at high risk for COPD reexacerbation or with comorbid symptoms to PCPs. The COPD CARE service, leveraged the patient-centered medical home (PCMH) model for transitions of care after COPD exacerbations. The PCMH is a primary care model focused on the following functions: (1) comprehensive care; (2) patient-centered care; (3) coordinated care; (4) accessible service; and (5) quality and safety. The COPD CARE service uniquely positions clinical pharmacists and nurses to collaborate with PCPs within the medical home model to serve patients with COPD postdischarge. This interprofessional collaboration is intended to provide timely and high-quality postdischarge care, including the triage of high-risk patients to primary care, referral services, and specialty care providers (eAppendix 1, available at mudege.com/fedprac).

METHODS

The COPD CARE service was implemented on October 1, 2015, and evaluated through March 1, 2016 (Figure 1). All veterans receiving primary care through the clinic with a hospital admission or ED visit for COPD exacerbation were offered this intervention. Patients were identified by discharge visit ICD-10 codes specific for COPD. The clinic nurse care manager spoke with patients on the phone and offered the COPD CARE service.

Patient Eligibility and Recruitment

Patients were excluded from the service if COPD or COPD-related diagnoses were not listed in their electronic health record (EHR) problem list. Patients who had previously received components of the intervention through consultation with specialty services were excluded. If a patient declined the service, they received the standard of care. This project was undertaken for programmatic evaluation and qualified for quality improvement (QI) exemption; as such an internal review board approval was not required.

Intervention

Participants enrolled in the COPD CARE service were scheduled for an interprofessional postdischarge follow-up visit with a pharmacist and nurse at the pilot outpatient clinic site, and this visit was termed the COPD CARE health visit. Participants ideally were seen within 30 days of discharge. The goal was to improve access to care while preventing a 30-day readmission. Within this 30-day window, the target follow-up period was 2 to 3 weeks postdischarge for the face-to-face visit. Patients who required postdischarge care for additional medical conditions received a clinic appointment with their PCP on the same day as their COPD CARE health visit. The COPD CARE health visit focused on 3 objectives: (1) COPD disease management and referrals, (2) COPD plan development, and (3) inhaler technique review and teaching.

COPD Monitoring

During the 45-minute COPD CARE health visit, the pharmacist provided extensive disease management based on the GOLD guideline recommendation. In addition, the pharmacist administered the COPD Assessment Test (CAT) and reviewed patient COPD exacerbation history to guide prescribing. The patient and pharmacist also reviewed previous spirometry results obtained within the past 2 years. COPD triggers and symptoms were assessed along with opportunities for therapeutic and lifestyle modifications.

Plan Development

Patients in the COPD CARE service also were given a COPD plan to improve health outcomes. (Figure 2) The plan included patient instructions to initiate steroid and antibiotic therapy if the patient experienced symptoms of increased cough, mucus
Reducing COPD Readmissions

FIGURE 1 COPD CARE Service Referral Process

COPD exacerbation resulting in either emergency department visit or hospitalization

Emergency department

Hospitalization

Chart review and ICD-10 diagnosis code indicates COPD exacerbation

48-h postdischarge telephone call by RN manager

Patient receives primary care at pilot clinic, is not followed by pulmonary service

Patient accepts and is enrolled in COPD CARE service

Acute care needs assessed by RN care manager

COPD and additional disease

COPD only

PCP visit scheduled

COPD CARE service scheduled

Patients were referred for the COPD CARE service after discharge from either the hospital or emergency department. All patients must have experienced a COPD exacerbation. Hospitalized patients were identified during a postdischarge telephone contact, while patients from the emergency department visit were identified through ICD-10 diagnosis codes and chart review. All patients meeting inclusion criteria were offered service participation during telephone contact by a registered nurse. Patients requiring postacute care management for multiple disease were also scheduled to see a PCP.

Abbreviations: COPD CARE service; Chronic Obstructive Pulmonary Disease; COPD, chronic obstructive pulmonary disease; PCP, primary care physician; RN, registered nurse.

Patient Referrals

Patient referrals also were a critical component of the COPD CARE service. Pharmacists placed referrals for tobacco treatment services, pulmonary rehabilitation, a COPD group education class, and referral to specialty care if needed.

Inhaler Technique Review

Either the pharmacist or RN review the inhaler technique, and corrections and teach-back methods used to ensure patient understanding. Patients were encouraged to bring home inhalers into clinic for technique assessment. Demonstration inhalers also were available and used by pharmacists and nurses for inhaler teaching as needed. The pharmacist indicated through chart documentation whether the patient’s inhaler technique was correct or whether modifications were made to improve medication delivery. Medication reconciliation also was performed for inhaled devices to ensure patients were using medications as prescribed.

OUTCOMES

The primary outcome of this evaluation was the assessment of interventions made by the care team during the COPD CARE health visit. Secondary outcomes included assessment of 30-day readmission rates as well as patient access to the primary care team using this interprofessional care model.

Data were collected after study completion through review of the EHR at baseline and at the end of the evaluation period. Baseline demographic information was collected through a retrospective chart review. Readmission rates were calculated as a composite of ED visits and rehospitalization within 30 days of discharge due to a COPD exacerbation. Patients’ spirometry results were used in composite with clinical symptoms and risk of exacerbations to calculate GOLD staging.

RESULTS

A total of 19 patients admitted to the hospital or ED received follow-up through the COPD CARE service. Patients included in this analysis were primarily older adult white males.

Referrals were placed for 53% of patients in the COPD CARE service, with 21% of patients accepting referral to tobacco treatment clinical, and 32% of patients accepting referral to pulmonary rehabilitation. COPD plans were issued to all of patients in this service. Pharmacists modified therapy 58% of the time, with a review of medications prescribed by the clinical pharmacist (Appendixes 1 and 2, available at mdedge.com/fedprac).

Patients had a 0% composite readmission rate to the ED or hospital for a COPD exacerbation within 30 days of discharge. Access to care, defined as a visit with the primary care PACT team within 30 days of discharge, was achieved in 14 of the 19 patients (73.7%). Additionally, 12 of 19 patients (63.2%) in the COPD CARE service no longer needed to see their PCP following discharge, saving their provider a visit.

The pharmacist corrected patient inhaler technique in 52.6% of the patients participating in the service.

DISCUSSION

The intent of this QI initiative was to assess a novel clinic intervention for a high-risk patient population during COPD care transitions. The strengths of this intervention involved a rapid cycle implementation using the existing medical home model and its multigun approach to coordinating care. This approach involved coordinating self-referral COPD plans, timely hospital follow-up, and the innovative use of the interprofessional primary care team.

The COPD CARE service improved patient access to follow-up with no COPD readmissions in the intervention group. The COPD CARE service also validated the use of a coordinated medical home consisting of clinical pharmacists and nurses who provided the initial COPD disease monitoring and plan development. This intervention also resulted in patients receiving greater access to their PACT teams within 30 days of discharge and a higher rate of referrals to tobacco cessation clinics within the COPD CARE group. In addition, use of tools that enabled patients to self-manage their care, such as the COPD plan, was greater in the COPD CARE group.
Chronic obstructive pulmonary disease (COPD) plan includes 4 zones:

1. Control long-term. 25 In addition, the high per-trait contributes to improvements in COPD disease outcomes. 25 Long-term disease outcomes, thereby determining whether the promised readmission results are sustained beyond 30 days post-discharge. 

The interventions made in-clinic likely contributed to service results (Appendix 3, available at mdedge.com/fedprac). Key in-structures were used to offer the service to eligible patients. This standard of care in-putting into practice improvement intervention with rapid triage high-risk patients (Appendix 4, available at mdedge.com/fedprac). The COPD CARE service involved the coor-dination of efforts by interprofessional teams to optimize care for COPD patients and therefore, at high risk for future COPD exacerbations. This initiative provides positive proof of a concept QI project using the existing PACT team model to reduce 30-day readmission rates in patients with COPD at high risk for exacerbation. Future efforts will focus on delivering this intervention to pa-tients with severe COPD within a wide range of primary clinics.

CONCLUSION The COPD CARE service involved the coordi-nation of discharge care facilitated by an interprofessional team of clinical pharmacists, nurses and PCPs. The COPD CARE service leveraged an interprofessional team, centered on the PACT medical home, to make clinic interventions resulting in a 0% readmission rate and 62.2% increase in FCP access. The COPD CARE service further demonstrated the impact of coordinated efforts by interprofessional teams to optimize care for COPD management.

Acknowledgments The authors thank Stephanie Gruber, PharmD; Lienie Kele, RN; Molly O’Brennan, PharmD; Jana Adams, RT; Mark Regan, MD; Chris Roeke, RN; Steve Seyer, PharmD; John Thiemann, RN; Sandy Tompkins, RN; and Wendi Wenger, RN, for their integral roles in the COPD CARE service.

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Forefront Medical Communications Inc., the US Government, or any of its agencies. This article may discuss and/or promote investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combina-tions—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Author Affiliations Edward Portillo is a Clinical Pharmacist Specialist, Andrew Wilcox is Chief of Pharmacy Services, Elaina Beckel is Acting Chief of Primary Care and Associate Chief of Ambulatory and Specialty Care, Amanda Margolis is a Clinical Pharmacist Specialist, Jean Montgomery is a Physician in Primary Care, Prakash Balasubramaniam is a Hospitalist, Giri Abhishek is the Service Line Manager and Nurse Manager-Primary Care, Jim Lewis is Chief of Respiratory Therapy, Christopher Hildebrand is the Associate Chief of Staff for Education and Ambulatory Care, Sameer Mathur is Associate Professor in the Division of Allergy, Pulmonary and Critical Care Medicine, Alan Bridges is Chief of Staff, and Sujani Kakumanu is Chief of Allergy, at the William S. Middleton Memorial Veterans Affairs Hospital in Madison, Wisconsin. Edward Portillo and Amanda Margolis are Clinical Assistant Professors at the University of Wisconsin-Madison School of Pharmacy. Christopher Hildebrand and Alan Bridges are Clinical Professors in the Department of Medicine, and Sameer Mathur is an Associate Professor at the University of Wisconsin-Madison School of Medicine and Public Health.

References


5. COPD Foundation. Patient groups back bill supporting US veterans with COPD. https://www.copdfoundation.org/About-Us/Press-Room/Press-Releases/Article/722
Reducing COPD Readmissions

36 • FEDERAL PRACTITIONER • NOVEMBER 2018

13. Kripalani S, Jackson AT, Schnipper JL, Coleman EA. Pro-